← Back to Search

Neuropsychological testing for Epilepsy

Phase 2
Waitlist Available
Research Sponsored by University of South Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2-4 months
Awards & highlights

Study Summary

The present study aims to expand the evidence base of neuropsychological services in the context of medical management of epilepsy, examining whether treatment outcome and patient satisfaction with medical care are significantly improved when neuropsychological evaluation is included as an additional component of medical care within a comprehensive epilepsy center. All participants will complete an initial survey and a follow-up survey regarding views towards their epilepsy treatment. Participants will be randomized into one of two groups. One group will be given a neuropsychological battery in addition to the survey. The primary study hypothesis is that the addition of neuropsychological services to treatment-as-usual will result in significant improvements in (a) satisfaction with medical care, (b) patient perceived treatment outcome, and (c) physician-rated medical compliance. The secondary hypothesis is that participants who undergo neuropsychological evaluation will be generally satisfied with their experience with neuropsychological services.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2-4 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2-4 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Epilepsy Outcome Study Survey

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Neuropsychological testingExperimental Treatment1 Intervention
Participants from this group will be administered a neuropsychological battery in addition to the initial and follow-up surveys
Group II: Treatment as usualActive Control1 Intervention
Participants from this group will be administered the initial and follow-up survey.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Neuropsychological testing
2017
N/A
~570

Find a Location

Who is running the clinical trial?

University of South FloridaLead Sponsor
410 Previous Clinical Trials
186,808 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~10 spots leftby Apr 2025